Erythropoietin and anemia of cancer

European Journal of Haematology

Volumn 64, Issue 6, 2000, Pages 353-358

  Erslev, Allan J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Anemia; Cancer; Erythropoiesis; Erythropoietin

Indexed keywords

CISPLATIN; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CELL CYCLE; DRUG EFFECT; ERYTHROCYTE; ERYTHROPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANEMIA; ERYTHROBLASTS; ERYTHROID PROGENITOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS;

EID: 0033916561     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.9R116.x     Document Type: Review

References (61)

1. 1. ORKIN SH. GATA-binding transcription factors in hematopoietic cells. Blood 1992;80:575-581.
2. 2. OLWEUS J, TERSTAPPEN LW, THOMPSON PA, LUND-JOHANSEN F. Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. Blood 1996;88:1594-1607.
3. 3. OGAWA M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-2853.
4. 4. SOSINSKI MA, CANNISTRA AS, ELIAS A, ANTMAN K, SCHNIPPER L, GRIFFIN JD. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;1:1194-1198.
5. 5. ERSLEV AJ. Erythropoietin. N Engl J Med 1991;324:1339-1344.
6. 6. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined Phase I and II clinical trial. N Engl J Med 1987;316:73-78.
7. 7. D'ANDREA AD, ZON LI. Erythropoietin receptor: Subunit structure and activation. J Clin Invest 1990;86:681.
8. 8. SAWADA K, KRANTZ SB, DAI CH, et al. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol 1990; 142:219.
9. 9. KOURY MJ, BONDURANT MC. Control of red cell production: The role of programmed cell death (apoptosis) and erythropoietin. Transfusion 1990;30:673.
10. L expression. Blood 1999;94: 87-96.
11. 11. EBERT BL, BUNN HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-1877.
12. 12. ORKIN SH, WEISS MJ. Cutting red-cell production. Nature 1999;401:433-436.
13. 13. ROSSO S, BELLI G. The prevalence of anemia in cancer patients: a nationwide survey in Italy. American Soc Clin Oncology 1998; abstract.
14. 14. MOLITERNO AR, SPIVAK JL. Anemia of cancer. Hematol Oncol Clin North Am 1996;10:345-363.
15. 15. ERSLEV AJ. Anemia associated with marrow infiltration. In: BEUTLER E, LICHTMAN MA, COLLER BS, KIPPS TJ, SELIGSOHN U, eds. Williams Hematology 6th edn, New York: McGraw-Hill (in press).
16. 16. HIRSCH FR, HANSEN HH. Bone marrow involvement in small cell anaplastic carcinoma of the lung: Prognostic and therapeutic aspects. Cancer 1980;46:206.
17. 17. ARGILES JM, LOPEZ-SORIANO FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999;19:223-248.
18. 18. MEANS RT, Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995;13: 32-37.
19. 19. ERSLEV AJ. Anemia of chronic disease. In: BEUTLER E, LICHTMAN MA, COLLER BS, KIPPS TJ, SELIGSOHN U, eds. Williams Hematology, 6th edn, New York: McGraw-Hill (in press).
20. 20. COTES PM, SPIVAK JL. Erythropoietin in health and disease. In: ERSLEV AJ, ADAMSON JW, ESCHBACH JW, WINEARLS CG, eds. Erythropoietin: Molecular, Cellular, and Clinical Biology. Baltimore: The Johns Hopkins University Press, 1991:184-207.
21. 21. JELKMANN W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokines Res 1998;18: 555-559.
22. 22. WANG GL, SEMENZA GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible Factor I DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 1993;82:3610-3615.
23. 23. MILLER CB, JONES RJ, PIANTADOSI S, ABELOFF MD, SPIVAK JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;14:1689-1692.
24. 24. MANTOVANI G, GHIANI M, CURRELI L, et al. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients. Oncol Rep 1999;6:421 426.
25. 25. CASCINU S, FEDELI A, DEL FERRO E, LUZI S, CATALANO G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-1062.
26. 26. THOMAS ML. Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Med Oncol 1998;1:S3-S7.
27. 27. VOGELZANG NJ, BREITBART W, CELLA D, et al. Patient, caregiver and physician perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 1997;34:4-12.
28. 28. THOMAS ML. Anemia and quality of life in cancer patients: impact of tranfusion and erythropoietin. Med Oncol 1998;1: S13-S18.
29. 29. LAUPACIS A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. Semin Nephrol 1990;10:11-19.
30. 30. DEMETRI DD, KRIS M, WADE J, DEGAS L, CELLA D. Quality-of-life benefits in chemotherapy patients with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16:4312-4325.
31. 31. FJORNES T, WIEDEMANN GJ, SACK K, JELKMANN W. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. Oncol Rep 1998;5:81-86.
32. 32. CAZZOLA M, PONCHIO L, PEDROTTI C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996;81:434-441.
33. 33. HENRY DH. Recombinant human erythropoietin treatment of anemic cancer patients. Cancer Pract 1996;4:180-184.
34. 34. DACOSTA NA, HULTIN MB. Effective therapy of human immunodeficiency virus-associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin. Am J Hematol 1991;36:71-72.
35. 35. DANIELSSON BG, GEISSER P, SCHNEIDER W. Iron therapy with special emphasis on intravenous administration. 1999, personal communication.
36. 36. SPIVAK JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
37. 37. SAN MIGUEL JF, GARCIA-SANZ R. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma. Med Oncol 1998;1:S29-S34.
38. 38. MACMILLAN ML, FREEDMAN MH. Recombinant human erythropoietin in children with cancer. J Pediatr Hematol Oncol 1998;20:187-189.
39. 39. ABELS RI, LARHOLT KM, KRANTZ KD, BRYANT EC. Recombinant human erythropoietin (rHuEpo) for the treatment of the anemia of cancer. Oncologist 1996;1:140-150.
40. 40. OSTER W, HERRMANN F, GAMM H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990;8:956-962.
41. 41. GLASPY J, BUKOWSKI R, STEINBERG D, TAYLOR C, TCHEKMEDYIAN S, VADHAM-RAJ S. Impact of therapy with epoietin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15: 1218-1234.
42. 42. CAZZOLA M, MESSINGER D, BATTISTEL V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or nonHodgkin lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-4453.
43. 43. NOWROUSSIAN MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemic in patients with solid tumours. Med Oncol 1998;1: S19-S28.
44. 44. TSUKUDA M, YUYAMA S, KOHNO H, ITOH K, KOKATSU T, KAWAI S. Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. Biotherapy 1998;11:21-25.
45. 45. PANGALIS G, POZIOPOULOS C, ANGELOPOULOU MK, SIAKANTARIS MP, PANAYIOTIDIS P. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukemia patients with recombinant human erythropoietin. Br J Haematology 1995; 89:627-629.
46. 46. OSTERBORG A. Recombinant human erythropoietin (rHuEpo) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998;1:S47-S49.
47. 47. DEL MASTRO L, VENTURINI M, LIONETTO R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-2721.
48. 48. JILANI SM, GLASPY JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol 1998;25:571-576.
49. 49. FLAHARTY KK, CARO J, ERSLEV AJ, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990;47:557-564.
50. 50. CAZZOLA M, MERCURIALI F, BRUGNARA C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89:4248-4267.
51. 51. NEUMAYER HH, BROCKMOLLER J, FRITSCHKA E, ROOTS I, SCIGALLA P, WATTENBERG M. Pharmacokinetics of rHEpo after s.c. administration and in long-term i.v. treatment in patients on maintenance hemodialysis. Contrib Nephrol 1989;776:1131.
52. 52. KAUFMAN JS, REDA DJ, FYE CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578-583.
53. 53. BEGUIN Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 1998;1:S38-S46.
54. 54. BEGUIN Y, CLEMONS G, POOTRAKUL P, FILLET G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067-1076.
55. 55. CSAKI C, FERENCZ T, SCHULER D, BORSI JD. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 1998;34:364-367.
56. 56. BAROSI G, MARCHETTI M, LIBERATO NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998;78:781 787.
57. 57. QUIRT I, MICUCCI S, MORAN LA, PATER J, BROWMAN G. Erythropoietin in the management of patients with non-hematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control 1997;1:241 248.
58. 58. WURNIG C, WINDHAGER R, SCHWAMEIS E, et al. Prevention of chemotherapy induced anemia by the use of erythropoietin in patients with primary malignant bone tumors. Transfusion 1996;36: 155-159.
59. 59. LAVEY RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 1998;4:24-30.
60. 60. MEADOWCROFT AM, GILBERT CJ, MARAVICH-MAY D, HAYWARD SL. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 1998;55: 1898-1902.
61. 61. ORTEGA A, DRANITSARIS G, PUODZIUNAS AL. What are cancer patients to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 1998;83:2588-2596.